GSK competitorsClear all
GSK's top competitors include Johnson & Johnson, Roche, AstraZeneca, Takeda Pharmaceutical, Bayer and Eli Lilly.
| Save Comparison |  Johnson & Johnson Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field. |  Roche Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics. |  AstraZeneca AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. |  Eli Lilly Eli Lilly and Company is a company that discovers, develops, manufactures, and markets pharmaceutical products. | |||
Founding Date | Founding Date 2000 | Founding Date 1886 | Founding Date 1896 | Founding Date 1999 | Founding Date 1781 | Founding Date 1863 | Founding Date 1876 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||||
Locations | Locations Brentford, GB HQ Tirane, AL Boudouaou, DZ Victoria, AR Abbotsford, AU Boronia, AU Ermington, AU see more | Locations New Brunswick, US HQ Buenos Aires, AR Chippendale, AU Wien, AT Minsk, BY Beerse, BE Brussel, BE see more | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Haedo, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU see more | Locations Tokyo, JP HQ The Rocks, AU Linz, AT Wien, AT Sint Jans Molenbeek, BE Santo Amaro, BR Toronto, CA see more | Locations Indianapolis, US HQ Melrose Park, AU Wien, AT Brussel, BE São Paulo, BR Toronto, CA Las Condes, CL see more | ||
Employees | Employees 99,4374% increase | Employees 132,2002% decrease | Employees 97,7353% increase | Employees 70,6009% increase | Employees 47,4954% decrease | Employees 101,1683% decrease | Employees 33,62513% decrease |
Valuation ($) | Valuation ($) 94.6 b | Valuation ($) 427.5 b | Valuation ($) N/A | Valuation ($) 137.8 b | Valuation ($) 54.1 b | Valuation ($) 63.8 b | Valuation ($) 192.5 b |
Twitter followers | Twitter followers 216 k | Twitter followers 214.5 k | Twitter followers 227.8 k | Twitter followers 230.5 k | Twitter followers N/A | Twitter followers 177.3 k | Twitter followers 126.6 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 36 | Number of tweets (last 30 days) 21 | Number of tweets (last 30 days) 31 | Number of tweets (last 30 days) 14 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 41 | Number of tweets (last 30 days) 30 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 21.2 | Average likes per tweet (last 30 days) 11.6 | Average likes per tweet (last 30 days) 21 | Average likes per tweet (last 30 days) 172.1 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 15.9 | Average likes per tweet (last 30 days) 10 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 80.56% | Percentage of tweets with engagement (last 30 days) 61.9% | Percentage of tweets with engagement (last 30 days) 80.65% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 68.29% | Percentage of tweets with engagement (last 30 days) 40% |
Alexa Website Rank | Alexa Website Rank 35293 | Alexa Website Rank 24994 | Alexa Website Rank 65169 | Alexa Website Rank 93263 | Alexa Website Rank 192980 | Alexa Website Rank 83024 | Alexa Website Rank 142814 |
Employee Rating | Employee Rating 4 | Employee Rating 4.1 | Employee Rating N/A | Employee Rating 4.2 | Employee Rating N/A | Employee Rating N/A | Employee Rating 3.9 |
Financial | |||||||
Revenue (est.) | Revenue (est.) £33.8b (FY, 2019) | Revenue (est.) $82.1b (FY, 2019) | Revenue (est.) CHF63.8b (FY, 2019) | Revenue (est.) $24.4b (FY, 2019) | Revenue (est.) ¥3.3t (FY, 2020) | Revenue (est.) €43.5b (FY, 2019) | Revenue (est.) $22.3b (FY, 2019) |
Cost of goods | Cost of goods £11.9b (FY, 2019) | Cost of goods $27.6b (FY, 2019) | Cost of goods CHF18.4b (FY, 2019) | Cost of goods $4.9b (FY, 2019) | Cost of goods ¥1.1t (FY, 2020) | Cost of goods €17.5b (FY, 2019) | Cost of goods $4.7b (FY, 2019) |
Gross profit | Gross profit £21.9b (FY, 2019) | Gross profit $54.5b (FY, 2019) | Gross profit CHF45.4b (FY, 2019) | Gross profit $19.5b (FY, 2019) | Gross profit ¥2.2t (FY, 2020) | Gross profit €26.1b (FY, 2019) | Gross profit $17.6b (FY, 2019) |
Net income | Net income £5.3b (FY, 2019) | Net income $15.1b (FY, 2019) | Net income CHF14.1b (FY, 2019) | Net income $1.2b (FY, 2019) | Net income ¥44.3b (FY, 2020) | Net income €2.4b (FY, 2019) | Net income $8.3b (FY, 2019) |
Operating ⚠ | |||||||
Countries | Countries N/A | Countries 60 (FY, 2018) | Countries N/A | Countries 100 (FY, 2019) | Countries N/A | Countries 153 (FY, 2018) | Countries 120 (FY, 2019) |
Filed Trials Products (Oncology) | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) 3 (Dec, 2020) | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) 8 (Oct, 2020) | Filed Trials Products (Oncology) N/A | Filed Trials Products (Oncology) N/A |
Manufacturing Facilities | Manufacturing Facilities 87 (FY, 2016) | Manufacturing Facilities 97 (FY, 2019) | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A | Manufacturing Facilities N/A |
Patients Included in Clinical Trials | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials 282.5 k (FY, 2019) | Patients Included in Clinical Trials 33 k (FY, 2017) | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A | Patients Included in Clinical Trials N/A |
Phase I Trials Products | Phase I Trials Products 12 (FY, 2019) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 27 (FY, 2019) |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 43 (Dec, 2020) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 1 (Jul, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 12 (Jan, 2020) | Phase II Trials Products 9 (FY, 2019) |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 7 (Dec, 2020) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 8 (Oct, 2019) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products 14 (FY, 2019) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 9 (Jan, 2020) | Phase III Trials Products 15 (FY, 2019) |
Phase III Trials Products (Neuroscience) | Phase III Trials Products (Neuroscience) N/A | Phase III Trials Products (Neuroscience) N/A | Phase III Trials Products (Neuroscience) 2 (Dec, 2020) | Phase III Trials Products (Neuroscience) N/A | Phase III Trials Products (Neuroscience) 1 (Feb, 2020) | Phase III Trials Products (Neuroscience) N/A | Phase III Trials Products (Neuroscience) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 26 (Dec, 2020) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 5 (Oct, 2020) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Projects in R&D Pipeline | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 167 (FY, 2019) | Projects in R&D Pipeline N/A | Projects in R&D Pipeline N/A | Projects in R&D Pipeline 66 (FY, 2016) |
Suppliers | Suppliers N/A | Suppliers 3.5 k (Jun, 2018) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 86.4 k (FY, 2019) | Suppliers N/A |
Funding | |||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 2.8b | Total funding raised $ 1b | Total funding raised $ 57.8m | Total funding raised $ 3.5b | Total funding raised N/A |
For sources of this data, please see the company profile
View company profiles
Johnson & Johnson
HQ
New Brunswick, US
Employees
132,200↓ 2% decrease
Johnson & Johnson is a global holding company that engages in the research and development, manufacture and sale of a range of products in the healthcare field.
View companyRoche
HQ
Basel, CH
Employees
97,735↑ 3% increase
Roche (also known as F. Hoffmann-La Roch) is a biotech company operating through 2 segments: Pharmaceuticals and Diagnostics.
View companyAstraZeneca
HQ
Cambridge, GB
Employees
70,600↑ 9% increase
AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
View company
Takeda Pharmaceutical
HQ
Tokyo, JP
Employees
47,495↓ 4% decrease
Takeda Pharmaceutical is a biopharmaceutical company.
View company